GSK to close historic Stevenage hub amid £1.9bn cost-saving plan

GSK, a major UK-based pharmaceutical firm, has announced plans to close its historic research hub in Stevenage. This move is part of a broader strategy to reduce costs by £1.9 billion over the coming years. The company expects to transfer research activities to a new state-of-the-art facility in Cambridge, which is anticipated to enhance its pipeline of medicines and vaccines.

The Stevenage site has been a longstanding part of GSK's research operations, but the company states that consolidating research efforts in Cambridge will improve efficiency and innovation. The closure is expected to lead to job reductions at the Stevenage location, though GSK has committed to managing the transition responsibly.

This restructuring reflects broader industry trends towards optimizing R&D investments and reducing operational costs amid competitive pressures and patent expirations. The move could impact local employment and regional biotech activity, but may also position GSK for more agile research capabilities.

Market analysts will be watching closely to see how this strategic shift influences GSK's future product development and financial performance, especially as the company reallocates resources to its new Cambridge site.